Journal of Clinical Medicine (Jun 2022)

Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes

  • María José Martínez,
  • Ferran Rueda,
  • Carlos Labata,
  • Teresa Oliveras,
  • Santiago Montero,
  • Marc Ferrer,
  • Nabil El Ouaddi,
  • Jordi Serra,
  • Josep Lupón,
  • Antoni Bayés-Genís,
  • Cosme García-García

DOI
https://doi.org/10.3390/jcm11123558
Journal volume & issue
Vol. 11, no. 12
p. 3558

Abstract

Read online

Cardiogenic shock (CS) is a severe complication of acute myocardial infarction (AMI). In AMI-CS, the ST segment deviation on ECG may be elevated (STEMI-CS) or non-elevated (NSTEMI-CS), which may influence prognosis. Our aim was to analyze the clinical profile, acute-phase prognosis, and long-term outcomes of CS relative to the ST pattern on admission. In a prospective registry of 4647 AMI patients admitted to the intensive cardiac care unit of a university hospital between 2010 and 2019, we compared the clinical characteristics, 30-days case fatality, and long-term outcomes of AMI-CS, based on the presence of ST-segment deviation. AMI-CS developed in 239 (5.1%) patients (26.4% women): 190 (79.5%) STEMI-CS and 49 (20.5%) NSTEMI-CS. The mean age was 69.7 years. The STEMI-CS patients had larger infarcts and more mechanical complications than the NSTEMI-CS patients. The NSTEMI-CS patients had a greater prevalence of hypertension, diabetes, peripheral vascular disease, previous cardiovascular comorbidities, three-vessel disease, and left main disease than the STEMI-CS patients. The STEMI-CS patients had higher 30-day mortality than the NSTEMI-CS (59.5% vs. 36.7%; p = 0.004), even after multivariable adjustment (HR 1.91; 95% CI 1.16–3.14), but no differences in mortality were observed at 3 years. In conclusion, the 30-day case-fatality is higher in STEMI-CS, but the long-term outcome is similar in both groups.

Keywords